296 related articles for article (PubMed ID: 26181671)
1. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
[No Abstract] [Full Text] [Related]
2. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Dillon B; Naidoo B; Knight H; Clark P
Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
[No Abstract] [Full Text] [Related]
3. Clairvoyance or reliable prediction of the future?
van Zandwijk N; van de Vijver MJ
Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
[No Abstract] [Full Text] [Related]
4. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors may change the metastatic pattern.
Sendur MA; Aksoy S; Ozdemir NY; Zengin N
J BUON; 2013; 18(2):544. PubMed ID: 23818376
[No Abstract] [Full Text] [Related]
6. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.
Yu HA; Tian SK; Drilon AE; Borsu L; Riely GJ; Arcila ME; Ladanyi M
JAMA Oncol; 2015 Oct; 1(7):982-4. PubMed ID: 26181354
[No Abstract] [Full Text] [Related]
7. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Hellmann MD; Reva B; Yu H; Rusch VW; Rizvi NA; Kris MG; Arcila ME
J Thorac Oncol; 2014 Oct; 9(10):e73-4. PubMed ID: 25521405
[No Abstract] [Full Text] [Related]
8. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
9. Molecular selection trumps clinical selection.
Shepherd FA
J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
[No Abstract] [Full Text] [Related]
10. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
11. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
Carney BJ; Rangachari D; VanderLaan PA; Gowen K; Schrock AB; Ali SM; Costa DB
Lung Cancer; 2017 Dec; 114():108-110. PubMed ID: 28870636
[No Abstract] [Full Text] [Related]
12. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
13. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Drpa G; Sreter KB; Manojlovic S; Kukulj S
Anticancer Drugs; 2018 Mar; 29(3):281-285. PubMed ID: 29280916
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
López-Brea M
Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
[No Abstract] [Full Text] [Related]
15. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
[TBL] [Abstract][Full Text] [Related]
17. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
18. Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.
Kim JS; Ryu JS; Jeon SH; Kim HJ; Nam HS; Cho JH; Kwak SM; Lee HL
J Int Med Res; 2018 Jan; 46(1):533-537. PubMed ID: 28730909
[TBL] [Abstract][Full Text] [Related]
19. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Berge EM; Aisner DL; Doebele RC
J Thorac Oncol; 2013 Sep; 8(9):e83-4. PubMed ID: 23945392
[No Abstract] [Full Text] [Related]
[Next] [New Search]
